Disorder of Vocal CordNCT02947009
Exercise-induced Paradoxical Vocal Fold Motion Disorder: Clinical Features and Potential Mechanisms
A study testing Diagnostic Study in people with Disorder of Vocal Cord, run by University of Pittsburgh at 1 site in United States.
Trial summary
Exercise-induced paradoxical vocal fold motion disorder (E-PVFMD) - which severely impacts the lives of up to 1 million adolescents in the U.S. annually - is under- or mis-diagnosed in as many as 80% of cases, leading to ineffective, protracted periods of management. Read more about this study
- Who is it for?
- Ages 12 to 18 years
- Conditions the study is for
- Disorder of Vocal Cord
- What is being tested?
- Diagnostic Study
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 27 participants
- Where
- 1 siteUnited States
- Study dates
- Nov 2016to 3 Jul 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Adolescents (ages 12-18yo)
- Exercise regularly (at least 40min 3x/week) in competitive athletic environment
- Inclusion criteria specific to E-PVFMD group: report of atypical dyspnea during exertion and associated decrements in athletic performance for more than 2 weeks prior to presentation; Score of > 10/40 on the Dyspnea Index
Who cannot join
- Developmental or cognitive disorder precluding ability to follow directions or read instructions
- Behavioral disorder that would disrupt study protocol or potentially affect outcome parameters (e.g., attention-deficit/hyperactivity disorder [ADHD], oppositional defiant disorder [ODD]).
- Neuromuscular disorders affecting the respiratory or phonatory system (e.g., ALS, Myasthenia Gravis)
- Supralaryngeal anatomical defects impeding airflow
- Cardiovascular conditions/disorders (e.g., hypertension)
- Poorly controlled obstructive pulmonary disorders (e.g., asthma)
Show all 11Show fewer
- Use of the following medications: (a) antihypertensive, (b) cardiovascular, (c) psychotropic
- Identifiable (organic) vocal fold pathology occluding more than a 1/3 of the airway (e.g., lesions, nodules), found on laryngeal examination
- Intolerance to flexible nasoendoscopy
- E-PVFMD group only: absence of signs or symptoms of acute E-PVFMD attack with exercise provocation challenge at maximum exertion at or before the 3minute mark.
- At-Risk group only: Positive signs or symptoms of an acute E-PVFMD attack with exercise provocation challenge at maximum exertion.
Trial locations and contacts
1 site in 1 country.
United States1 site
Mass Eye and Ear Infirmary
Boston, Massachusetts, 02114
About this study
Official title: Exercise-induced Paradoxical Vocal Fold Motion Disorder: Clinical Feature Characteristics and Potential Mechanisms
Exercise-induced paradoxical vocal fold motion disorder (E-PVFMD) - which severely impacts the lives of up to 1 million adolescents in the U.S. annually - is under- or mis-diagnosed in as many as 80% of cases, leading to ineffective, protracted periods of management. Additionally, what makes those with the condition different from those at risk for the condition (e.g., playing sports/engaging in athletic activity within a competitive athletic environment) is unclear. The goals of this proposed study are to address this diagnostic challenge by (1) pursuing a previously published preliminary taxonomic algorithm for the clinical identification and classification of EPVFMD, and by (2) elucidating potential underlying mechanisms driving this clinical presentation. Study outcomes will improve sensitivity and specificity of diagnosis protocols for PVFMD, thereby reducing prevalence of misdiagnosis and improving clinical management in individuals with this disorder in the future. Outcomes will also be used to create preventative care measures for adolescents at risk for the condition.
Read the detailed description
The experimental protocol consists of five stages in total (Stages IV): (1) Screening, (2) Pre-Baseline, (3) Baseline Laryngoscopy Condition, (4) Exercise Laryngoscopy Condition, and (5) Recovery. The following sections describe procedures conducted within each of the five stages
Stage I: Screening
To determine eligibility, all consenting participants will (1) undergo spirometric screening to rule out any indication of pulmonary pathology, (2) report they partake in athletic activity within a competitive environment (self-perceived/reported), and (3) complete the Dyspnea Index (DI). Participants with less than 80% predicted FEV1 on spirometry will be excluded from the study and referred to the pediatric pulmonary clinic at Massachusetts General Hospital (MGH). Anyone who reports they feel their sports-related activities are not competitive will be excluded. Participants in the E-PVFMD group who score less than 10 out of 40 on the DI will be excluded from the study, whereas participants in the at-risk group who score more than 6 out of 40 on the DI will be excluded from the study.
Stage II: PreBaseline
All participants who have passed the screening will rate the worst severity of perceived shortness of breath experienced during the screening period, as well as other symptoms relating to PVFMD (i.e., cough, globus, dysphonia, laryngeal pain/tension), on a 0100mm visual analog scale (VAS). These values will later serve as anchors for subsequent symptom ratings. Rating severity of symptoms prior to laryngoscopy will also prime participants for symptom severity ratings in subsequent conditions, described shortly in detail. Next, blood pressure (SBP) and heart rate (HR) readings will be obtained three times (x3) at 30-second intervals or greater over a 5minute period, using a blood and heart rate monitor. The three readings will then be averaged and used as anchors for SBP and HR readings taken during subsequent study phases. Two self-reported questionnaires will then be administered to all enrolled participants: the Early Adolescent Temperament Questionnaire - Revised-short form (EATQ-R-SF) and the Paffenbarger Physical Activity Questionnaire (PPAQ). Participants will read and complete the two questionnaires on their own, although the PI or parent/guardian may clarify questions or help participants read instructions, especially with younger participants. Last, a respiratory transducer band will be placed on ribs 5-8 to measure respiratory rate (RR) and tidal volumes (TV). These parameters may be used to stratify/bin data, posthoc.
Stage III: Baseline Laryngoscopy Condition
Participants will be positioned upright in an examination chair and given a decongestant (e.g., Afrin®) in one nasal passage. The laryngeal vestibule will then be visualized with flexible nasoendoscopy (laryngoscopy) using halogen light. Subjects with structural or dynamic abnormalities occluding more than a third of the airway will be ruled out (and excluded, as needed) and normal laryngeal movement (i.e., abduction on inspiration and slight adduction on exhalation) will be confirmed at rest by both clinician and ENT physician. The laryngeal examination will then be recorded and glottic and supraglottic laryngeal configuration will be analyzed later offline. The PI will watch the participant's thoracic and abdominal cavity movement and will call the beginning of each inspiratory ("I") and expiratory ("E") phase as the participant breathes. The calls will be recorded on laryngeal examination videos and used to identify optimal periods within specific phases of the respiratory cycle from which to extract digital still images of the larynx. Participants will be asked to remain as relaxed as possible, but instructions will not relate to breathing so as not to bring attention to respiratory patterns. Three SBP and HR readings will be recorded for the second time with a blood pressure cuff every 30 seconds or more over a 5min period and averaged across the three trials. Once the endoscope has been removed, participants will be asked to rate perception of their worst severity of shortness of breath experienced during the baseline laryngoscopy condition on the 0-100mm VAS for the second time.
Stage IV: Exercise Laryngoscopy Condition
Participants will then undergo a graded exercise test (GXT) with cycle ergometer and simultaneous flexible laryngoscopy. The exercise challenge will parallel procedures in a previously described 1minute progressive incremental cycle ergometer protocol, starting at 50 watts (300 kgm/min), with increments of 50 watts every minute. Simultaneous laryngoscopic procedures, as well as SBP and HR recordings, will generally parallel those of the baseline laryngoscopic protocol in Stage III. To minimize risk of injury or overexertion, explicit instructions for the exercise protocol will be given to each participant prior to the start of the protocol. Once participants have communicated understanding, they will sit on the ergometer and the seat will be properly adjusted so there is a slight bend in the knee joint when the ball of the foot is on the pedal, with the pedal in its lowest position (~10-15° angle of knee flexion when the leg is extended). Once seated in position, participants will be instructed to relax the grip of the handlebar to prevent peripheral constriction, which could confound cardiovascular functions. The blood pressure cuff will be adjusted accordingly in the standard fashion and a pulse oximeter will be fitted on the participant's middle finger of the dominant hand to monitor oxyhemoglobin saturation during the exercise challenge. Participants will then be trained on rating perceived levels of exertion by pointing to the Borg Perceived Exertion Scale mounted on a board. The Borg scale goes from 6 to 20, where 6 represents no feelings of exertion and a score of 19 represents anaerobic activity that cannot be sustained for more than a minute. Borg severity ratings will be used to identify optimal level of exertion for measures extracted from video images during the exercise condition. During this task, participants will be encouraged not to vocalize and will be asked to rely solely on the board to communicate their perceived level of exertion for each incremental exercise load that will be imposed. The goal of this endeavor is to avoid movement of the vocal folds with vocalization, which may confound respiratory (non-phonatory) laryngeal configuration parameters. A head mount will then be placed on the participant's head and the head of the flexible endoscope will be inserted into the head mount, with the flexible camera dangling from the head mount below the head of the endoscope. Next, participants will be reminded of the Borg Scale ratings, and re-instructed as needed. For participants with potential E-PVFMD, instructions will also be provided to indicate induction of PVFMD attack with a "thumbs up" signal during the provocation challenge. All participants will be informed they will be encouraged to continue pedaling throughout the protocol until vigorous exercise levels are reached. Participants will also be reminded the protocol is voluntary and they can terminate the trial at any time. Once participants have communicated understanding and their willingness to continue, the flexible camera lens will once again be inserted into the same nostril, in the same manner as for the baseline laryngoscopy examination. Once the laryngeal vestibule has been identified with the laryngoscope, the flexible camera lens will then be secured to the ipsilateral nare with surgical tape to prevent movement of the scope in and out of the nose. The graded exercise test (GXT) will then begin at 50 watts (300 kgm/min) with target increases of 300 kgm/min every minute, per standard GXT protocol. Participants will be asked to maintain a 50-70 RPM pedal rate (displayed on the ergometer) with each incremental increase in load. For participants in the E-PVFMD group, incremental loads will continue until one of two events transpires: (1) E-PVFMD attack occurs (i.e., the participant experiences symptoms representative of previously experienced paroxysmal PVFMD episodes, and indicates induction of the episode with a "thumbs up" sign). Once the episode begins, videoendoscopy recordings will be obtained for an additional 30 seconds before the exercise laryngoscopy challenge is terminated, at which point the video recording will also be stopped. (2) No signs/symptoms of "attack" occur at the 3-minute mark with maximum exertion (19-20 Borg score), and the challenge is terminated. Results in these latter cases will be binned for future analysis beyond the scope of the proposed study. However, the sans-PVFMD-attack cohort in the PVFMD group will be excluded from analysis for the final n=25 in the present study and replaced until the targeted sample size (n = 25) has been reached. For the at-risk group, once a score of 19 on the Borg scale has been reported, 30 additional seconds of videoendoscopy will be recorded before the task is terminated. To terminate the protocol for both groups, the bike ergometer will first be reduced to 0 watts load and the laryngoscope will be removed from the nasopharynx. During the exertion task, SBP and HR will be recorded at the one minute mark, right before each additional incremental increase in load, and then again 1-2 times during maximum exertion (Borg scale 19-20) within the 30-second maximum exercise challenge (and subsequent videoendoscopic recording time frame). Participants will be on the bike a maximum of 10 minutes.
Stage V: Recovery
The cycle ergometer task will be stopped and SBP and HR will once again be recorded, this time at the 1-minute, 2-minute, and 3-minute post-max exertion time points, determined by a stopwatch. Participants will be asked to rate their worst perceived symptoms experienced during the exercise laryngoscopy task for the third (and final time) time using the 0-100 VAS. HR readings will then be used to calculate heart rate recovery (HRR) offline for further data analysis. Participants will then cycle for an additional 1-2 min for proper cool down to ensure cardiovascular parameters are back to baseline before they are helped off the bike.
- Conditions
- Disorder of Vocal Cord
- Being tested
- Diagnostic Study
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Diagnostic StudyBehavioural
Participants will undergo laryngoscopy at baseline and with exercise challenge and will rate severity of various symptoms related to the larynx (ex. shortness of breath, voice changes, cough).
| Study group | Role | What they receive |
|---|---|---|
| Adolescent athletes with PVFMD | Experimental | participants must be adolescents (ages 12-18yo) who exercise regularly (at least 40 min 3x/week) and engage in athletic activities competitively by their report.
Any participant who declares he or she is a competitive athlete and presents to the clinic reporting atypical dyspnea during exertion and associated decrements in athletic performance for more than 2 weeks prior to presentation will be considered for the study. Participants must score at least a 10 out of 40 on the Dyspnea Index Receives: Behavioral: Diagnostic Study |
| Adolescent athletes at-risk for PVFMD | Active comparator | participants must be adolescents (ages 12-18yo) who exercise regularly (at least 40 min 3x/week) and engage in athletic activities competitively by their report.
Participants in the at-risk group must report playing sports in a competitive environment, must report no symptoms of atypical dyspnea over the past 6 months, and must score less than 6 out of 40 on the Dyspnea Index. Receives: Behavioral: Diagnostic Study |
What is being measured
The primary outcome is the main question the study is designed to answer.
Estimates of vocal fold angle at anterior commissure, determined on laryngoscopic digital images taken at height of inspiration prior to start of exhalation
Measured: 1 year
Self-report of dyspnea severity, determined on 100mm visual analog scale
Measured: 1 year
Secondary outcomes (6)
Amount arytenoid prolapse, rated on a 0-3 scale based on videoendoscopic images
Measured: 1 year
Amount of epiglottic collapse, rated on a 0-3 scale based on videoendoscopic images
Measured: 1 year
Amount of ventricular compression, rated on a 0-3 scale based on videoendoscopic images
Measured: 1 year
Self-report of cough severity, determined based on 100mm visual analog scale
Measured: 1 year
Self-report of neck tightness severity, determined based on 100mm visual analog scale
self-reported ratings of symptoms of cough, globus sensation, neck tightness, dysphonia, and stridor
Measured: 1 year
Self-report of stridor severity, determined based on 100mm visual analog scale
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Oct 2016 (estimated)
- Study startNov 2016
- Primary completion3 Jul 2017
- Study completion3 Jul 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (21)Papers the sponsor has linked to this study.
- Other trials for Disorder of Vocal CordStudies of the same condition, open and under way.
- More trials run by University of PittsburghThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Factorial
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 27 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Pittsburgh
- Sponsor type
- University, hospital or other
- Collaborators
- Massachusetts Eye and Ear Infirmary
- Responsible party
- Principal investigator, Adrianna Shembel, University of Pittsburgh
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02947009
- Sponsor's protocol ID
- 1F31DC015752-01A1
- Status last verified
- Oct 2016
- First submitted
- 19 Oct 2016
- Last updated
- 14 Aug 2017
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Publications
Abu-Hasan M, Tannous B, Weinberger M. Exercise-induced dyspnea in children and adolescents: if not asthma then what? Ann Allergy Asthma Immunol. 2005 Mar;94(3):366-71. doi: 10.1016/S1081-1206(10)60989-1.
PubMed 15801248Al-Alwan A, Kaminsky D. Vocal cord dysfunction in athletes: clinical presentation and review of the literature. Phys Sportsmed. 2012 May;40(2):22-7. doi: 10.3810/psm.2012.05.1961.
PubMed 22759602Altman KW, Mirza N, Ruiz C, Sataloff RT. Paradoxical vocal fold motion: presentation and treatment options. J Voice. 2000 Mar;14(1):99-103. doi: 10.1016/s0892-1997(00)80099-5.
PubMed 10764121Bittleman DB, Smith RJ, Weiler JM. Abnormal movement of the arytenoid region during exercise presenting as exercise-induced asthma in an adolescent athlete. Chest. 1994 Aug;106(2):615-6. doi: 10.1378/chest.106.2.615.
PubMed 7774352Carter JB, Banister EW, Blaber AP. Effect of endurance exercise on autonomic control of heart rate. Sports Med. 2003;33(1):33-46. doi: 10.2165/00007256-200333010-00003.
PubMed 12477376Christensen PM, Thomsen SF, Rasmussen N, Backer V. Exercise-induced laryngeal obstructions: prevalence and symptoms in the general public. Eur Arch Otorhinolaryngol. 2011 Sep;268(9):1313-9. doi: 10.1007/s00405-011-1612-0. Epub 2011 Apr 29.
PubMed 21528411Christopher KL, Morris MJ. Vocal cord dysfunction, paradoxic vocal fold motion, or laryngomalacia? Our understanding requires an interdisciplinary approach. Otolaryngol Clin North Am. 2010 Feb;43(1):43-66, viii. doi: 10.1016/j.otc.2009.12.002.
PubMed 20172256Coote JH. Recovery of heart rate following intense dynamic exercise. Exp Physiol. 2010 Mar;95(3):431-40. doi: 10.1113/expphysiol.2009.047548. Epub 2009 Oct 16.
PubMed 19837772Fahey JT, Bryant NJ, Karas D, Goldberg B, Destefano R, Gracco LC. Exercise-induced stridor due to abnormal movement of the arytenoid area: videoendoscopic diagnosis and characterization of the "at risk" group. Pediatr Pulmonol. 2005 Jan;39(1):51-5. doi: 10.1002/ppul.20076.
PubMed 15558600Gartner-Schmidt JL, Shembel AC, Zullo TG, Rosen CA. Development and validation of the Dyspnea Index (DI): a severity index for upper airway-related dyspnea. J Voice. 2014 Nov;28(6):775-82. doi: 10.1016/j.jvoice.2013.12.017. Epub 2014 Oct 12.
PubMed 25311596Johansson H, Norlander K, Berglund L, Janson C, Malinovschi A, Nordvall L, Nordang L, Emtner M. Prevalence of exercise-induced bronchoconstriction and exercise-induced laryngeal obstruction in a general adolescent population. Thorax. 2015 Jan;70(1):57-63. doi: 10.1136/thoraxjnl-2014-205738. Epub 2014 Nov 7.
PubMed 25380758Langdeau JB, Turcotte H, Desagne P, Jobin J, Boulet LP. Influence of sympatho-vagal balance on airway responsiveness in athletes. Eur J Appl Physiol. 2000 Nov;83(4 -5):370-5. doi: 10.1007/s004210000306.
PubMed 11138577Newman KB, Mason UG 3rd, Schmaling KB. Clinical features of vocal cord dysfunction. Am J Respir Crit Care Med. 1995 Oct;152(4 Pt 1):1382-6. doi: 10.1164/ajrccm.152.4.7551399.
PubMed 7551399Noyes BE, Kemp JS. Vocal cord dysfunction in children. Paediatr Respir Rev. 2007 Jun;8(2):155-63. doi: 10.1016/j.prrv.2007.05.004.
PubMed 17574160Pierpont GL, Voth EJ. Assessing autonomic function by analysis of heart rate recovery from exercise in healthy subjects. Am J Cardiol. 2004 Jul 1;94(1):64-8. doi: 10.1016/j.amjcard.2004.03.032.
PubMed 15219511
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exercise-induced Paradoxical Vocal Fold Motion Disorder: Clinical Feature Characteristics and Potential Mechanisms
- ClinicalTrials.gov ID
- NCT02947009
- Acronym / sponsor ID
- 1F31DC015752-01A1
- Conditions
- Disorder of Vocal Cord
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 27 participants (actual)
- Lead sponsor
- University of PittsburghUniversity, hospital or other
- Collaborators
- Massachusetts Eye and Ear Infirmary
- Study start
- Nov 2016
- Primary completion
- 3 Jul 2017 (actual)
- Study completion
- 3 Jul 2017 (actual)
- First posted
- 27 Oct 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Exercise-induced paradoxical vocal fold motion disorder (E-PVFMD) - which severely impacts the lives of up to 1 million adolescents in the U.S. annually - is under- or mis-diagnosed in as many as 80% of cases, leading to ineffective, protracted periods of management. Additionally, what makes those with the condition different from those at risk for the condition (e.g., playing sports/engaging in athletic activity within a competitive athletic environment) is unclear. The goals of this proposed study are to address this diagnostic challenge by (1) pursuing a previously published preliminary taxonomic algorithm for the clinical identification and classification of EPVFMD, and by (2) elucidating potential underlying mechanisms driving this clinical presentation. Study outcomes will improve sensitivity and specificity of diagnosis protocols for PVFMD, thereby reducing prevalence of misdiagnosis and improving clinical management in individuals with this disorder in the future. Outcomes will also be used to create preventative care measures for adolescents at risk for the condition.
Detailed description
The experimental protocol consists of five stages in total (Stages IV): (1) Screening, (2) Pre-Baseline, (3) Baseline Laryngoscopy Condition, (4) Exercise Laryngoscopy Condition, and (5) Recovery. The following sections describe procedures conducted within each of the five stages
Stage I: Screening
To determine eligibility, all consenting participants will (1) undergo spirometric screening to rule out any indication of pulmonary pathology, (2) report they partake in athletic activity within a competitive environment (self-perceived/reported), and (3) complete the Dyspnea Index (DI). Participants with less than 80% predicted FEV1 on spirometry will be excluded from the study and referred to the pediatric pulmonary clinic at Massachusetts General Hospital (MGH). Anyone who reports they feel their sports-related activities are not competitive will be excluded. Participants in the E-PVFMD group who score less than 10 out of 40 on the DI will be excluded from the study, whereas participants in the at-risk group who score more than 6 out of 40 on the DI will be excluded from the study.
Stage II: PreBaseline
All participants who have passed the screening will rate the worst severity of perceived shortness of breath experienced during the screening period, as well as other symptoms relating to PVFMD (i.e., cough, globus, dysphonia, laryngeal pain/tension), on a 0100mm visual analog scale (VAS). These values will later serve as anchors for subsequent symptom ratings. Rating severity of symptoms prior to laryngoscopy will also prime participants for symptom severity ratings in subsequent conditions, described shortly in detail. Next, blood pressure (SBP) and heart rate (HR) readings will be obtained three times (x3) at 30-second intervals or greater over a 5minute period, using a blood and heart rate monitor. The three readings will then be averaged and used as anchors for SBP and HR readings taken during subsequent study phases. Two self-reported questionnaires will then be administered to all enrolled participants: the Early Adolescent Temperament Questionnaire - Revised-short form (EATQ-R-SF) and the Paffenbarger Physical Activity Questionnaire (PPAQ). Participants will read and complete the two questionnaires on their own, although the PI or parent/guardian may clarify questions or help participants read instructions, especially with younger participants. Last, a respiratory transducer band will be placed on ribs 5-8 to measure respiratory rate (RR) and tidal volumes (TV). These parameters may be used to stratify/bin data, posthoc.
Stage III: Baseline Laryngoscopy Condition
Participants will be positioned upright in an examination chair and given a decongestant (e.g., Afrin®) in one nasal passage. The laryngeal vestibule will then be visualized with flexible nasoendoscopy (laryngoscopy) using halogen light. Subjects with structural or dynamic abnormalities occluding more than a third of the airway will be ruled out (and excluded, as needed) and normal laryngeal movement (i.e., abduction on inspiration and slight adduction on exhalation) will be confirmed at rest by both clinician and ENT physician. The laryngeal examination will then be recorded and glottic and supraglottic laryngeal configuration will be analyzed later offline. The PI will watch the participant's thoracic and abdominal cavity movement and will call the beginning of each inspiratory ("I") and expiratory ("E") phase as the participant breathes. The calls will be recorded on laryngeal examination videos and used to identify optimal periods within specific phases of the respiratory cycle from which to extract digital still images of the larynx. Participants will be asked to remain as relaxed as possible, but instructions will not relate to breathing so as not to bring attention to respiratory patterns. Three SBP and HR readings will be recorded for the second time with a blood pressure cuff every 30 seconds or more over a 5min period and averaged across the three trials. Once the endoscope has been removed, participants will be asked to rate perception of their worst severity of shortness of breath experienced during the baseline laryngoscopy condition on the 0-100mm VAS for the second time.
Stage IV: Exercise Laryngoscopy Condition
Participants will then undergo a graded exercise test (GXT) with cycle ergometer and simultaneous flexible laryngoscopy. The exercise challenge will parallel procedures in a previously described 1minute progressive incremental cycle ergometer protocol, starting at 50 watts (300 kgm/min), with increments of 50 watts every minute. Simultaneous laryngoscopic procedures, as well as SBP and HR recordings, will generally parallel those of the baseline laryngoscopic protocol in Stage III. To minimize risk of injury or overexertion, explicit instructions for the exercise protocol will be given to each participant prior to the start of the protocol. Once participants have communicated understanding, they will sit on the ergometer and the seat will be properly adjusted so there is a slight bend in the knee joint when the ball of the foot is on the pedal, with the pedal in its lowest position (~10-15° angle of knee flexion when the leg is extended). Once seated in position, participants will be instructed to relax the grip of the handlebar to prevent peripheral constriction, which could confound cardiovascular functions. The blood pressure cuff will be adjusted accordingly in the standard fashion and a pulse oximeter will be fitted on the participant's middle finger of the dominant hand to monitor oxyhemoglobin saturation during the exercise challenge. Participants will then be trained on rating perceived levels of exertion by pointing to the Borg Perceived Exertion Scale mounted on a board. The Borg scale goes from 6 to 20, where 6 represents no feelings of exertion and a score of 19 represents anaerobic activity that cannot be sustained for more than a minute. Borg severity ratings will be used to identify optimal level of exertion for measures extracted from video images during the exercise condition. During this task, participants will be encouraged not to vocalize and will be asked to rely solely on the board to communicate their perceived level of exertion for each incremental exercise load that will be imposed. The goal of this endeavor is to avoid movement of the vocal folds with vocalization, which may confound respiratory (non-phonatory) laryngeal configuration parameters. A head mount will then be placed on the participant's head and the head of the flexible endoscope will be inserted into the head mount, with the flexible camera dangling from the head mount below the head of the endoscope. Next, participants will be reminded of the Borg Scale ratings, and re-instructed as needed. For participants with potential E-PVFMD, instructions will also be provided to indicate induction of PVFMD attack with a "thumbs up" signal during the provocation challenge. All participants will be informed they will be encouraged to continue pedaling throughout the protocol until vigorous exercise levels are reached. Participants will also be reminded the protocol is voluntary and they can terminate the trial at any time. Once participants have communicated understanding and their willingness to continue, the flexible camera lens will once again be inserted into the same nostril, in the same manner as for the baseline laryngoscopy examination. Once the laryngeal vestibule has been identified with the laryngoscope, the flexible camera lens will then be secured to the ipsilateral nare with surgical tape to prevent movement of the scope in and out of the nose. The graded exercise test (GXT) will then begin at 50 watts (300 kgm/min) with target increases of 300 kgm/min every minute, per standard GXT protocol. Participants will be asked to maintain a 50-70 RPM pedal rate (displayed on the ergometer) with each incremental increase in load. For participants in the E-PVFMD group, incremental loads will continue until one of two events transpires: (1) E-PVFMD attack occurs (i.e., the participant experiences symptoms representative of previously experienced paroxysmal PVFMD episodes, and indicates induction of the episode with a "thumbs up" sign). Once the episode begins, videoendoscopy recordings will be obtained for an additional 30 seconds before the exercise laryngoscopy challenge is terminated, at which point the video recording will also be stopped. (2) No signs/symptoms of "attack" occur at the 3-minute mark with maximum exertion (19-20 Borg score), and the challenge is terminated. Results in these latter cases will be binned for future analysis beyond the scope of the proposed study. However, the sans-PVFMD-attack cohort in the PVFMD group will be excluded from analysis for the final n=25 in the present study and replaced until the targeted sample size (n = 25) has been reached. For the at-risk group, once a score of 19 on the Borg scale has been reported, 30 additional seconds of videoendoscopy will be recorded before the task is terminated. To terminate the protocol for both groups, the bike ergometer will first be reduced to 0 watts load and the laryngoscope will be removed from the nasopharynx. During the exertion task, SBP and HR will be recorded at the one minute mark, right before each additional incremental increase in load, and then again 1-2 times during maximum exertion (Borg scale 19-20) within the 30-second maximum exercise challenge (and subsequent videoendoscopic recording time frame). Participants will be on the bike a maximum of 10 minutes.
Stage V: Recovery
The cycle ergometer task will be stopped and SBP and HR will once again be recorded, this time at the 1-minute, 2-minute, and 3-minute post-max exertion time points, determined by a stopwatch. Participants will be asked to rate their worst perceived symptoms experienced during the exercise laryngoscopy task for the third (and final time) time using the 0-100 VAS. HR readings will then be used to calculate heart rate recovery (HRR) offline for further data analysis. Participants will then cycle for an additional 1-2 min for proper cool down to ensure cardiovascular parameters are back to baseline before they are helped off the bike.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Factorial
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Adolescent athletes with PVFMD | Experimental | Behavioral: Diagnostic Studyparticipants must be adolescents (ages 12-18yo) who exercise regularly (at least 40 min 3x/week) and engage in athletic activities competitively by their report. Any participant who declares he or she is a competitive athlete and presents to the clinic reporting atypical dyspnea during exertion and associated decrements in athletic performance for more than 2 weeks prior to presentation will be considered for the study. Participants must score at least a 10 out of 40 on the Dyspnea Index |
| Adolescent athletes at-risk for PVFMD | Active comparator | Behavioral: Diagnostic Studyparticipants must be adolescents (ages 12-18yo) who exercise regularly (at least 40 min 3x/week) and engage in athletic activities competitively by their report. Participants in the at-risk group must report playing sports in a competitive environment, must report no symptoms of atypical dyspnea over the past 6 months, and must score less than 6 out of 40 on the Dyspnea Index. |
Who may qualify
- Ages
- 12 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (3 listed)
- Adolescents (ages 12-18yo)
- Exercise regularly (at least 40min 3x/week) in competitive athletic environment
- Inclusion criteria specific to E-PVFMD group: report of atypical dyspnea during exertion and associated decrements in athletic performance for more than 2 weeks prior to presentation; Score of > 10/40 on the Dyspnea Index
Key exclusion criteria (11 listed)
- Developmental or cognitive disorder precluding ability to follow directions or read instructions
- Behavioral disorder that would disrupt study protocol or potentially affect outcome parameters (e.g., attention-deficit/hyperactivity disorder [ADHD], oppositional defiant disorder [ODD]).
- Neuromuscular disorders affecting the respiratory or phonatory system (e.g., ALS, Myasthenia Gravis)
- Supralaryngeal anatomical defects impeding airflow
- Cardiovascular conditions/disorders (e.g., hypertension)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Diagnostic StudyParticipants will undergo laryngoscopy at baseline and with exercise challenge and will rate severity of various symptoms related to the larynx (ex. shortness of breath, voice changes, cough). | Behavioural | Adolescent athletes at-risk for PVFMD, Adolescent athletes with PVFMD |
Primary outcome
Estimates of vocal fold angle at anterior commissure, determined on laryngoscopic digital images taken at height of inspiration prior to start of exhalation
Time frame: 1 year
Self-report of dyspnea severity, determined on 100mm visual analog scale
Time frame: 1 year
6 secondary outcomes
Amount arytenoid prolapse, rated on a 0-3 scale based on videoendoscopic images
Time frame: 1 year
Amount of epiglottic collapse, rated on a 0-3 scale based on videoendoscopic images
Time frame: 1 year
Amount of ventricular compression, rated on a 0-3 scale based on videoendoscopic images
Time frame: 1 year
Self-report of cough severity, determined based on 100mm visual analog scale
Time frame: 1 year
Self-report of neck tightness severity, determined based on 100mm visual analog scale
Time frame: 1 year
Self-report of stridor severity, determined based on 100mm visual analog scale
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2017.
- Background: PubMed 15801248Abu-Hasan M, Tannous B, Weinberger M. Exercise-induced dyspnea in children and adolescents: if not asthma then what? Ann Allergy Asthma Immunol. 2005 Mar;94(3):366-71. doi: 10.1016/S1081-1206(10)60989-1.
- Background: PubMed 22759602Al-Alwan A, Kaminsky D. Vocal cord dysfunction in athletes: clinical presentation and review of the literature. Phys Sportsmed. 2012 May;40(2):22-7. doi: 10.3810/psm.2012.05.1961.
- Background: PubMed 10764121Altman KW, Mirza N, Ruiz C, Sataloff RT. Paradoxical vocal fold motion: presentation and treatment options. J Voice. 2000 Mar;14(1):99-103. doi: 10.1016/s0892-1997(00)80099-5.
- Background: PubMed 7774352Bittleman DB, Smith RJ, Weiler JM. Abnormal movement of the arytenoid region during exercise presenting as exercise-induced asthma in an adolescent athlete. Chest. 1994 Aug;106(2):615-6. doi: 10.1378/chest.106.2.615.
- Background: PubMed 12477376Carter JB, Banister EW, Blaber AP. Effect of endurance exercise on autonomic control of heart rate. Sports Med. 2003;33(1):33-46. doi: 10.2165/00007256-200333010-00003.
- Background: PubMed 21528411Christensen PM, Thomsen SF, Rasmussen N, Backer V. Exercise-induced laryngeal obstructions: prevalence and symptoms in the general public. Eur Arch Otorhinolaryngol. 2011 Sep;268(9):1313-9. doi: 10.1007/s00405-011-1612-0. Epub 2011 Apr 29.
- Background: PubMed 20172256Christopher KL, Morris MJ. Vocal cord dysfunction, paradoxic vocal fold motion, or laryngomalacia? Our understanding requires an interdisciplinary approach. Otolaryngol Clin North Am. 2010 Feb;43(1):43-66, viii. doi: 10.1016/j.otc.2009.12.002.
- Background: PubMed 19837772Coote JH. Recovery of heart rate following intense dynamic exercise. Exp Physiol. 2010 Mar;95(3):431-40. doi: 10.1113/expphysiol.2009.047548. Epub 2009 Oct 16.
- Background: PubMed 15558600Fahey JT, Bryant NJ, Karas D, Goldberg B, Destefano R, Gracco LC. Exercise-induced stridor due to abnormal movement of the arytenoid area: videoendoscopic diagnosis and characterization of the "at risk" group. Pediatr Pulmonol. 2005 Jan;39(1):51-5. doi: 10.1002/ppul.20076.
- Background: PubMed 25311596Gartner-Schmidt JL, Shembel AC, Zullo TG, Rosen CA. Development and validation of the Dyspnea Index (DI): a severity index for upper airway-related dyspnea. J Voice. 2014 Nov;28(6):775-82. doi: 10.1016/j.jvoice.2013.12.017. Epub 2014 Oct 12.
- Background: PubMed 25380758Johansson H, Norlander K, Berglund L, Janson C, Malinovschi A, Nordvall L, Nordang L, Emtner M. Prevalence of exercise-induced bronchoconstriction and exercise-induced laryngeal obstruction in a general adolescent population. Thorax. 2015 Jan;70(1):57-63. doi: 10.1136/thoraxjnl-2014-205738. Epub 2014 Nov 7.
- Background: PubMed 11138577Langdeau JB, Turcotte H, Desagne P, Jobin J, Boulet LP. Influence of sympatho-vagal balance on airway responsiveness in athletes. Eur J Appl Physiol. 2000 Nov;83(4 -5):370-5. doi: 10.1007/s004210000306.
- Individual participant dataSharing planned: No
Related trials for Disorder of Vocal Cord
Not yet recruiting
Endotracheal Tube Versus Transcartilage Needle Electrodes for Nerve Monitoring in Thyroid Surgery
Thyroid Diseases, Recurrent Laryngeal Nerve Injury
Not yet recruitingObservational study
Laryngotracheal Lesions in Adults With Long-Term Tracheostomy
Laryngotracheal Lesions, Tracheostomy Complications
RecruitingPhase 2
Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients
Head and Neck Disorder, Head and Neck Cancer
Not yet recruiting
Intranasal Dexmedetomidine Combined With Esketamine for Emergence Quality After Suspension Laryngoscopy
Emergence Agitation, Vocal Cord Polyps
Recruiting
The Impact of Hyperbaric Oxygen Therapy on Vocal Performance in Professional Singers
Vocal Cord Strain (Disorder)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Diagnostic Study in people with Disorder of Vocal Cord, run by University of Pittsburgh at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Estimates of vocal fold angle at anterior commissure, determined on laryngoscopic digital images taken at height of inspiration prior to start of exhalation (time frame: 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02947009, which also lists 21 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2017.